Market Introduction
Protein expression is a process in which proteins are synthesized, modified and regulated. Protein expression involves laboratory techniques & procedures which aid in manufacture of proteins. The technique allows to produce and purify the desired protein, either inside or outside a cell. The proteins synthesized using protein expression technique can be used for industrial processes or to diagnose and to treat diseases.
Thus, the growing adoption of precision medicines are expected to create a significant demand for protein expression in the coming years, which is further anticipated to drive the protein expression market.
In Dec. 2020, QIAGEN has launched its QuantiFERON SARS-CoV-2 RUO solution that can detect human immune system T-cell responses to the COVID-19-causing pathogen, which may help researchers, learn more about immunity levels and disease progression. Further, the Dyadic’s proprietary C1 expressed receptor binding domain (RBD) of the SARS-CoV-2 spike protein is being used in animal trials by seven research groups, governmental agencies and biopharma companies, including the Israel Institute for Biological Research (IIBR) and a collaboration of European Union scientists participating in the ZAPI programme. However, the demand for protein expression in market in Europe during is likely to increase as the rapidly growing cases of Covid -19 and prevalence of diseases such as cancer needs research for drug development where use of protein expression is important, hence it can boost the growth of the protein expression market.
Market Overview and Dynamics
The Protein expression market in Europe is expected to grow from US$ 690.1 million in 2021 to US$ 1,214.6 million by 2028; it is estimated to grow at a CAGR of 8.4% from 2021 to 2028. In November 2018, Stilla Technologies announced the completion of a Series A financing round of US$ 18.3 million (€16 million) led by Illumina Ventures. The company will use the funds to commercialize its Naica digital PCR system and develop clinical applications. In March 2018, SynbiCITE (UK) received around US$ 17.6 million (£13 million) grants and US$ 318.5 million (£234 million) private investment. SynbiCITE is made for increasing synbio applications in the UK. The SynbiCITE has supported the synbio at the national level for the growth of gene synthesis applications. Thus, the continuous funding by the manufacturers and governments in genomics and proteomics is expected to create lucrative opportunities for the growth of the protein expression market in the coming years.
Key Market Segments
In terms of product, the reagents segment accounted for the largest share of the Europe protein expression market in 2020. In terms of services, the antibody development and production segment accounted for the largest share of the Europe protein expression market in 2020. In terms of application, the therapeutic segment accounted for the largest share of the Europe protein expression market in 2020. In terms of end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the Europe protein expression market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the protein expression market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., GenScript, Merck KGaA, Agilent Technologies, Inc., Takara Bio Inc., Bio-Rad Laboratories Inc., QIAGEN, Oxford Expression Technologies, New England Biolabs, and Promega Corporation.
Reasons to buy report
- To understand the Europe Protein expression market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe Protein expression market
- Efficiently plan M&A and partnership deals in Europe Protein expression market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe Protein expression market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
EUROPE PROTEIN EXPRESSION MARKET SEGMENTATION
By Product
- Competent Cells
- Expression Vectors
- Reagents
- Instruments
By Services
- Antibody Development & Production
- Protein Expression & Production
- Hybridoma One-Stop Services
- Stable Cell Line Development
- Bioanalytical Assay Services
By Application
- Research
- Therapeutic
- Industrial
By End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Others
By Country
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Companies Mentioned
- Thermo Fisher Scientific Inc.
- GenScript
- Merck KGaA
- Agilent Technologies, Inc.
- Takara Bio Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN
- New England Biolabs
- Promega Corporation
- Oxford Expression Technologies
Europe Protein Expression Market Strategic Insights
Europe Protein Expression Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 690.1 Million |
| Market Size by 2028 | US$ 1,214.6 Million |
| CAGR (2021 - 2028) | 8.4% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
Europe Protein Expression Market Country and Regional Insights
